The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer

IF 5 2区 医学 Q2 Medicine Translational Oncology Pub Date : 2024-10-05 DOI:10.1016/j.tranon.2024.102140
Sumit Mallick , Asim K Duttaroy , Suman Dutta
{"title":"The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer","authors":"Sumit Mallick ,&nbsp;Asim K Duttaroy ,&nbsp;Suman Dutta","doi":"10.1016/j.tranon.2024.102140","DOIUrl":null,"url":null,"abstract":"<div><div>The <em>PIK3CA</em> gene is a linchpin in the intricate molecular network governing triple-negative breast cancer (TNBC) tumor tropism, serving as a focal point for understanding this aggressive disease. Anchored within the PI3K/AKT/mTOR signaling axis, <em>PIK3CA</em> mutations exert substantial influence, driving cellular processes that highlight the unique biology of TNBC. This review meticulously highlights the association between <em>PIK3CA</em> mutations and distinct TNBC subtypes, elucidating the gene's multifaceted contributions to tumor tropism. Molecular dissection reveals how <em>PIK3CA</em> mutations dynamically modulate chemokine responses, growth factor signaling, and extracellular matrix interactions, orchestrating the complex migratory behaviour characteristic of TNBC cells. A detailed exploration of <em>PIK3CA</em>-targeted strategies in the therapeutic arena is presented, outlining the current landscape of clinical trials and precision medicine approaches. As the scientific narrative converges, this review underscores the critical role of <em>PIK3CA</em> in shaping the molecular intricacies of TNBC tumor tropism and illuminates pathways toward tailored interventions, promising a paradigm shift in the clinical management of TNBC.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"50 ","pages":"Article 102140"},"PeriodicalIF":5.0000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324002675","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The PIK3CA gene is a linchpin in the intricate molecular network governing triple-negative breast cancer (TNBC) tumor tropism, serving as a focal point for understanding this aggressive disease. Anchored within the PI3K/AKT/mTOR signaling axis, PIK3CA mutations exert substantial influence, driving cellular processes that highlight the unique biology of TNBC. This review meticulously highlights the association between PIK3CA mutations and distinct TNBC subtypes, elucidating the gene's multifaceted contributions to tumor tropism. Molecular dissection reveals how PIK3CA mutations dynamically modulate chemokine responses, growth factor signaling, and extracellular matrix interactions, orchestrating the complex migratory behaviour characteristic of TNBC cells. A detailed exploration of PIK3CA-targeted strategies in the therapeutic arena is presented, outlining the current landscape of clinical trials and precision medicine approaches. As the scientific narrative converges, this review underscores the critical role of PIK3CA in shaping the molecular intricacies of TNBC tumor tropism and illuminates pathways toward tailored interventions, promising a paradigm shift in the clinical management of TNBC.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PIK3CA 基因及其在三阴性乳腺癌肿瘤滋养过程中的关键作用。
PIK3CA 基因是支配三阴性乳腺癌(TNBC)肿瘤趋向的复杂分子网络中的关键,是了解这种侵袭性疾病的焦点。PIK3CA 基因突变锚定在 PI3K/AKT/mTOR 信号转导轴上,对 TNBC 的细胞过程产生了重大影响,凸显了 TNBC 独特的生物学特性。这篇综述细致地强调了PIK3CA突变与不同TNBC亚型之间的关联,阐明了该基因对肿瘤滋养的多方面贡献。分子剖析揭示了PIK3CA突变如何动态调节趋化因子反应、生长因子信号转导和细胞外基质相互作用,从而协调TNBC细胞特有的复杂迁移行为。本文详细探讨了治疗领域的 PIK3CA 靶向策略,概述了当前的临床试验和精准医疗方法。随着科学叙事的汇聚,这篇综述强调了 PIK3CA 在形成 TNBC 肿瘤向性错综复杂的分子过程中的关键作用,并阐明了实现定制干预的途径,有望实现 TNBC 临床管理模式的转变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.40
自引率
2.00%
发文量
314
审稿时长
54 days
期刊介绍: Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
期刊最新文献
Clinical efficacies of different neoadjuvant therapies for non-small cell lung cancer Integrated multi-omics demonstrates enhanced antitumor efficacy of donafenib combined with FADS2 inhibition in hepatocellular carcinoma Disruption of bioenergetics enhances the radio-sensitivity of patient-derived glioblastoma tumorspheres KRas plays a negative role in regulating IDO1 expression Comparative transcriptomic analysis uncovers molecular heterogeneity in hepatobiliary cancers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1